Drug
Fianlimab
Fianlimab: highest development phase Phase 3, developed by Regeneron. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Regeneron
Trials
| Drug | Phase | Indication |
|---|---|---|
| fianlimab NCT06246916 | Phase 3 | Melanoma |
| Fianlimab NCT05352672 | Phase 3 | Melanoma |
| Fianlimab NCT05608291 | Phase 3 | Melanoma |
| Fianlimab NCT06161441 | Phase 2 | Resectable Non-small Cell Lung Cancer |
Latest
No recent events.
Follow Fianlimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.